Optosurgical, LLC

Optosurgical, LLC, a for-profit small business based in Columbia, Maryland, develops advanced surgical imaging systems and image-guided interventional technologies for the National Institutes of Health as a prime contractor under the total small business set-aside. The vendor operates exclusively as a prime (100% of awards) and has received no federal subcontract work.

Optosurgical's federal footprint centers on NIH-funded research and development in surgical visualization and intraoperative guidance. The company has completed or is executing three SBIR Phase II contracts totaling $9.1 million in combined potential value, all under NIH auspices. The largest active award is a $3.5 million Phase II SBIR contract from the Advanced Research Projects Agency for Health (ARPA-H), a component of NIH, for development of an advanced imaging-aided autonomous robotic cholecystectomy system (awarded September 22, 2023, with ultimate completion September 21, 2026). A second $3.5 million ARPA-H Phase II SBIR award funds intraoperative contrast agents for surgical imaging (awarded September 15, 2023, completing December 19, 2025). Most recently, on April 8, 2026, NIH awarded a $2.1 million definitive SBIR Phase II contract for translation of a novel biliary tract-specific contrast agent to enable image-guided hepatobiliary interventions, completing January 9, 2029. The company has also served as a recipient on two federal grants from NIH institutes: a National Institute of Biomedical Imaging and Bioengineering project grant (completed September 22, 2023) for biliary-specific fluorescence image-guided surgery using short-wave infrared imaging technology, and a National Institute of Diabetes and Digestive and Kidney Diseases project grant (completed August 31, 2023) for dye-free, multimodal laparoscopic imaging to assess bowel perfusion during colorectal resection. The latter grant reflects a partnership with Children's National Hospital for clinical validation and translational support.

Customer concentration is absolute: the Department of Health and Human Services National Institutes of Health accounts for 100% of recorded awards. Within NIH, the National Institute of Biomedical Imaging and Bioengineering and the Advanced Research Projects Agency for Health dominate the funding pipeline. The company carries no GWAC, BPA, or IDV vehicles in the source data. Activity has been episodic — two awards in 2020, two in 2021, two in 2023, and one in April 2026 — with one award (the $3.5 million ARPA-H contract completing December 19, 2025) facing recompete inside the next twenty-four months. SCI-reported invoiced revenue on federal services contracts totaled $3.3 million in FY2024 across 4.9 FTEs delivered to the government, with median government-paid rates around $155.70 per hour and senior labor pricing extending through $353.33 per hour. The vendor delivers all work in-house, with zero subcontractor hours reported across SCI-captured prime contracts. Optosurgical's capability portfolio is narrowly specialized in translating bench-stage medical imaging and surgical robotics research toward commercial-stage devices and intraoperative guidance systems, with an emphasis on hepatobiliary and colorectal surgical applications.